CA3062452C - Compositions, combinations, and methods thereof for treatment of neurological disorders - Google Patents

Compositions, combinations, and methods thereof for treatment of neurological disorders Download PDF

Info

Publication number
CA3062452C
CA3062452C CA3062452A CA3062452A CA3062452C CA 3062452 C CA3062452 C CA 3062452C CA 3062452 A CA3062452 A CA 3062452A CA 3062452 A CA3062452 A CA 3062452A CA 3062452 C CA3062452 C CA 3062452C
Authority
CA
Canada
Prior art keywords
compound
hydrogen
phenoxy
propan
deramciclane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3062452A
Other languages
English (en)
French (fr)
Other versions
CA3062452A1 (en
Inventor
Sreenivasarao Vepachedu
Hans J. MOEBIUS
Anton Bespalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exciva GmbH
Original Assignee
Exciva GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Application filed by Exciva GmbH filed Critical Exciva GmbH
Priority to CA3138116A priority Critical patent/CA3138116A1/en
Publication of CA3062452A1 publication Critical patent/CA3062452A1/en
Application granted granted Critical
Publication of CA3062452C publication Critical patent/CA3062452C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CA3062452A 2017-05-04 2018-05-03 Compositions, combinations, and methods thereof for treatment of neurological disorders Active CA3062452C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3138116A CA3138116A1 (en) 2017-05-04 2018-05-03 Novel compositions, combinations, and methods thereof

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
US62/501,696 2017-05-04
USPCT/US2017/048748 2017-08-25
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169 2017-08-28
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US62/634,162 2018-02-22
US201862636099P 2018-02-27 2018-02-27
US201862635554P 2018-02-27 2018-02-27
US62/636,099 2018-02-27
US62/635,554 2018-02-27
US201862636171P 2018-02-28 2018-02-28
US62/636,171 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3138116A Division CA3138116A1 (en) 2017-05-04 2018-05-03 Novel compositions, combinations, and methods thereof

Publications (2)

Publication Number Publication Date
CA3062452A1 CA3062452A1 (en) 2018-11-08
CA3062452C true CA3062452C (en) 2023-10-24

Family

ID=65431106

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3062452A Active CA3062452C (en) 2017-05-04 2018-05-03 Compositions, combinations, and methods thereof for treatment of neurological disorders
CA3138116A Pending CA3138116A1 (en) 2017-05-04 2018-05-03 Novel compositions, combinations, and methods thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3138116A Pending CA3138116A1 (en) 2017-05-04 2018-05-03 Novel compositions, combinations, and methods thereof

Country Status (13)

Country Link
EP (1) EP3618819A4 (https=)
JP (2) JP7514078B2 (https=)
KR (2) KR20200062078A (https=)
CN (1) CN110831584B (https=)
AU (2) AU2018261654A1 (https=)
BR (1) BR112019022902A2 (https=)
CA (2) CA3062452C (https=)
IL (1) IL270326B2 (https=)
MA (1) MA49464A (https=)
RU (1) RU2760558C9 (https=)
TW (1) TWI787260B (https=)
WO (1) WO2018204713A1 (https=)
ZA (1) ZA201908006B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA49464A (fr) * 2017-05-04 2020-04-29 Exciva GmbH Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants
TW202102219A (zh) * 2019-03-18 2021-01-16 美商艾賓爾製藥公司 使用氘化右旋美沙芬(dextromethorphan)及奎尼丁(quinidine)治療精神分裂症之負面徵候之方法
JP7400818B2 (ja) * 2019-06-06 2023-12-19 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
KR20240096817A (ko) 2020-05-19 2024-06-26 사이빈 아이알엘 리미티드 중수소화된 트립타민 유도체 및 사용 방법
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法
CN119432479B (zh) * 2023-08-04 2025-10-03 中国石油天然气股份有限公司 柴油机润滑油组合物及其制备方法
CN120987847B (zh) * 2024-11-29 2026-02-17 江苏恩华药业股份有限公司 一种氢溴酸右美沙芬的制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
TWI326214B (en) * 2002-07-17 2010-06-21 Avanir Pharmaceuticals Inc Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
CA2641392A1 (en) 2006-02-03 2007-08-16 Avanir Pharmaceuticals Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders
US7973049B2 (en) * 2007-05-01 2011-07-05 Concert Pharmaceuticals Inc. Morphinan compounds
EP2162135A4 (en) * 2007-05-21 2012-02-22 Reviva Pharmaceuticals Inc COMPOSITIONS, SYNTHESIS AND METHOD FOR THE APPLICATION OF ATTAINED CHINOLINONE-BASED ANTIPSYCHOTICS
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
US9737531B2 (en) * 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
EP2964022B1 (en) * 2013-03-07 2019-11-06 Mindlab LLC Pain medicine combination and uses thereof
AU2014232869A1 (en) * 2013-03-15 2015-10-08 Patrizia Fanara Methods for monitoring the effects of an agent in sujects with motoneuron disease with dementia
CN117427077A (zh) * 2014-09-14 2024-01-23 阿瓦尼尔制药股份有限公司 用于治疗痴呆中的激越行为的包含右美沙芬化合物和奎尼丁的药物组合物
US11103499B2 (en) * 2016-08-26 2021-08-31 EXCIVA (UG) (haftungsbeschränkt) Compositions and methods thereof
MA49464A (fr) * 2017-05-04 2020-04-29 Exciva GmbH Targeted drug rescue avec de nouvelles compositions, associations et procédés correspondants

Also Published As

Publication number Publication date
AU2018261654A1 (en) 2019-11-14
KR102444803B1 (ko) 2022-09-19
KR20210130827A (ko) 2021-11-01
RU2760558C9 (ru) 2022-02-22
AU2021215274A1 (en) 2021-09-02
CN110831584A (zh) 2020-02-21
RU2019137004A3 (https=) 2021-06-04
IL270326B (en) 2022-10-01
TW201842902A (zh) 2018-12-16
IL270326B2 (en) 2023-02-01
KR20200062078A (ko) 2020-06-03
JP7514078B2 (ja) 2024-07-10
CN110831584B (zh) 2023-03-10
WO2018204713A1 (en) 2018-11-08
TWI787260B (zh) 2022-12-21
RU2019137004A (ru) 2021-06-04
CA3138116A1 (en) 2018-11-08
EP3618819A4 (en) 2021-01-20
MA49464A (fr) 2020-04-29
ZA201908006B (en) 2021-04-28
JP2020518617A (ja) 2020-06-25
BR112019022902A2 (pt) 2020-05-19
IL270326A (https=) 2018-05-03
RU2760558C2 (ru) 2021-11-29
JP2023143940A (ja) 2023-10-06
CA3062452A1 (en) 2018-11-08
AU2021215274B2 (en) 2022-11-03
EP3618819A1 (en) 2020-03-11

Similar Documents

Publication Publication Date Title
CA3062452C (en) Compositions, combinations, and methods thereof for treatment of neurological disorders
AU2017315947B2 (en) Compositions and methods thereof
US20200261442A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
US20200069674A1 (en) Targeted drug rescue with novel compositions, combinations, and methods thereof
JP2024508545A (ja) セロトニン作動性薬に関係する障害の治療に有用なセロトニン作動性薬としてのインドール誘導体
JP2011502977A (ja) 多発性硬化症および自己免疫性脊髄炎の治療における３，１１Ｂ−ｃｉｓ−ジヒドロテトラベナジンの使用
US20110190333A1 (en) Dihydrotetrabenanzine for the treatment of anxiety
US20220296586A1 (en) Novel compositions, combinations, and methods thereof
WO2007020631A2 (en) Tetracyclic benzofuran derivatives with therapeutic activities

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191104

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250410

K11 Ip right revival requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-K10-K11-K100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVERSAL REQUEST RECEIVED

Effective date: 20251031

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 4TH ANNIV.) - SMALL

Year of fee payment: 4

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 6TH ANNIV.) - SMALL

Year of fee payment: 6

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - SMALL

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251103

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251107

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260217

H13 Ip right lapsed

Free format text: ST27 STATUS EVENT CODE: N-4-6-H10-H13-H100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE AND LATE FEE NOT PAID BY DEADLINE OF NOTICE

Effective date: 20260220

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260220

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260224

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20260312